Современная ревматология (Jun 2024)

Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study

  • A. M. Lila,
  • I. Z. Gaydukova,
  • O. N. Anoshenkova,
  • I. G. Bannikova,
  • I. B. Vinogradova,
  • M. L. Goldman,
  • S. Yu. Davidian,
  • L. P. Evstigneeva,
  • O. E. Epifanova,
  • E. V. Zemerova,
  • A. I. Zagrebneva,
  • L. V. Ivanova,
  • A. K. Karibova,
  • I. V. Menshikova,
  • O. N. Mironenko,
  • M. P. Mikhailova,
  • N. E. Nikulenkova,
  • I. M. Patrikeeva,
  • T. V. Plaksina,
  • G. R. Savvina,
  • R. R. Samigullina,
  • L. E. Sarantseva,
  • J. V. Usacheva,
  • O. P. Ukhanova,
  • G. F. Fatkhullina,
  • A. L. Chudinov,
  • I. A. Shafieva,
  • S. P. Yakupova

DOI
https://doi.org/10.14412/1996-7012-2024-3-32-43
Journal volume & issue
Vol. 18, no. 3
pp. 32 – 43

Abstract

Read online

The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of LVL in RA patients. Objective: to evaluate the efficacy and safety of LVL in the treatment of patients with RA in real-world clinical practice. Materials and methods. The HELIOS study is a retrospective-prospective, multicenter, non-interventional study of retention rate of LVL therapy and the safety of LVL in patients with RA in real-world clinical practice. Patients received medical care, including LVL, according to routine clinical practice for the treatment of RA and Russian instructions for medical use of the drug. This article presents the results of an analysis of the efficacy and safety of LVL after 12 and 24 weeks of treatment. Efficacy was assessed using the DAS28-CRP/ESR, SDAI, CDAI and patient assessment of pain, fatigue and morning stiffness according to VAS (0–100 mm). Results and discussion. 524 patients from 42 medical centers in the Russian Federation were enrolled in the study from June 2022 to November 2023. The majority of patients were female (83.2 %) and the mean age of patients was 53 years. A statistically significant decrease in DAS28-CRP/ESR, SDAI, CDAI, patient assessment of pain, fatigue and morning stiffness (VAS) was observed after 12 and 24 weeks of treatment, regardless of previous treatment with biologics or Jak inhibitors (JAKi). LVL was well tolerated by patients, the most frequently reported adverse events were infections, changes in peripheral blood and laboratory abnormalities characteristic of treatment with IL-6R inhibitors. Conclusion. In real-world clinical practice, LVL has been shown to be highly effective and well tolerated in patients with RA when prescribed as the first biologic disease-modifying antirheaumatic drus (bDMARD) and after switching from other bDMARDs or JAKi.

Keywords